180 related articles for article (PubMed ID: 23713330)
1. [A study on the HA amount of HA influenza vaccination on efficacy and safety in infants].
Takahashi H; Yano T; Fukuta M; Yamauchi A; Okuma K; Ihara T; Nakano T; Matsuda T; Torigoe S; Nii R; Isaji M; Watanabe M; Ochiai H; Sakatoku H; Kato T; Maeda K; Okuno Y; Kamiya H
Kansenshogaku Zasshi; 2013 Mar; 87(2):195-206. PubMed ID: 23713330
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of a Trivalent Influenza HA vaccine in Indonesian infants and children.
Soedjatmiko S; Medise BE; Gunardi H; Sekartini R; Satari HI; Hadinegoro SR; Bachtiar NS; Sari RM
Vaccine; 2018 Apr; 36(16):2126-2132. PubMed ID: 29551225
[TBL] [Abstract][Full Text] [Related]
3. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
4. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
[TBL] [Abstract][Full Text] [Related]
5. [Immune protective effectiveness of seasonal influenza spilt vaccine against homologous and heterogonous subtypes of influenza virus in mice].
Huang BY; Wang XP; Wang WL; Hu W; Gao Q; Tan WJ; Ruan L
Bing Du Xue Bao; 2011 May; 27(3):265-73. PubMed ID: 21774253
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial.
Nolan T; McVernon J; Skeljo M; Richmond P; Wadia U; Lambert S; Nissen M; Marshall H; Booy R; Heron L; Hartel G; Lai M; Basser R; Gittleson C; Greenberg M
JAMA; 2010 Jan; 303(1):37-46. PubMed ID: 20026597
[TBL] [Abstract][Full Text] [Related]
7. Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients.
Chang YT; Guo CY; Tsai MS; Cheng YY; Lin MT; Chen CH; Shen D; Wang JR; Sung JM
Vaccine; 2012 Jul; 30(33):5009-18. PubMed ID: 22658967
[TBL] [Abstract][Full Text] [Related]
8. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
[TBL] [Abstract][Full Text] [Related]
9. The priming effect of previous natural pandemic H1N1 infection on the immunogenicity to subsequent 2010-2011 influenza vaccination in children: a prospective cohort study.
Kang EK; Eun BW; Kim NH; Lim JS; Lee JA; Kim DH
BMC Infect Dis; 2016 Aug; 16(1):438. PubMed ID: 27549626
[TBL] [Abstract][Full Text] [Related]
10. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
Gorse GJ; Falsey AR; Fling JA; Poling TL; Strout CB; Tsang PH
Vaccine; 2013 May; 31(19):2358-65. PubMed ID: 23499604
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.
Knuf M; Leroux-Roels G; Rümke H; Rivera L; Pedotti P; Arora AK; Lattanzi M; Kieninger D; Cioppa GD
Hum Vaccin Immunother; 2015; 11(2):358-76. PubMed ID: 25621884
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing antibody but not hemagglutination antibody provides accurate evaluation for protective immune response to H5N1 avian influenza virus in vaccinated rabbits.
Zhu H; Ding X; Chen X; Yao P; Xu F; Xie R; Yang Z; Liang W; Zhang Y; Li Y; Shen J; He P; Guo Z; Su B; Sun S; Zhu Z
Vaccine; 2011 Jul; 29(33):5421-3. PubMed ID: 21645575
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC
Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
[TBL] [Abstract][Full Text] [Related]
15. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
Dong PM; Li YQ; Zheng TZ; Jia YP; Li F; Han TW; Qiao RX; Zhang BH
Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul; 24(7):570-3. PubMed ID: 12975010
[TBL] [Abstract][Full Text] [Related]
16. Vaccine failure and serologic response to live attenuated and inactivated influenza vaccines in children during the 2013-2014 season.
King JP; McLean HQ; Meece JK; Levine MZ; Spencer SM; Flannery B; Belongia EA
Vaccine; 2018 Feb; 36(9):1214-1219. PubMed ID: 29395525
[TBL] [Abstract][Full Text] [Related]
17. Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial.
Plennevaux E; Blatter M; Cornish MJ; Go K; Kirby D; Wali M; Reeves-Hoché MK; Denis M
Vaccine; 2011 Feb; 29(8):1569-75. PubMed ID: 21219979
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of monovalent influenza A (H1N1) 2009 in HIV-infected Thai children.
Phongsamart W; Sirisanthana V; Wittawatmongkol O; Maleesatharn A; Sudjaritruk T; Chearskul P; Aurpibul L; Sirisanthana T; Chokephaibulkit K
Vaccine; 2011 Nov; 29(47):8705-11. PubMed ID: 21893147
[TBL] [Abstract][Full Text] [Related]
20. Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized trial in Japanese children aged 6 months to 17 years.
Saitoh A; Nagai A; Tenjinbaru K; Li P; Vaughn DW; Roman F; Kato T
Hum Vaccin Immunother; 2012 Jun; 8(6):749-58. PubMed ID: 22495117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
